Avance Clinical signs MOUs with key Korean trial sites at 2024 KoNECT

CHA University Bundang Medical Center an advanced 1,000 bed hospital with a focus on patient care, research and education. Designated as a Research-Driven Hospital, it is committed to delivering a stable research environment and infrastructure to support the latest research and state-of-the-art medical technology. This partnership with Avance Clinical will further the reach and impact the hospital has on healthcare development globally.

Signed on October 28, 2024

Young-Sang Kim, Director for CHA Global Clinical Trials Center (CHA University Bundang Medical Center) shared his enthusiasm for the collaboration, remarking, “Partnering with Avance Clinical presents a valuable opportunity to expand our clinical trial expertise, especially in early-phase research. We believe this collaboration will not only strengthen our capabilities but also enable us to offer cutting-edge therapeutic solutions that will impact patients on a global scale”.

Korea University Medicine (Seoul), is a leading academic and medical institution recognized for its robust clinical trial capabilities. This partnership aims to accelerate clinical research opportunities, leveraging Korea University Medicine’s expertise to drive the development of innovative therapeutics.

Signed on October 29, 2024

Hak Jun Kim, President for Medical Research & Business Foundation of Korea University Medicine expressed optimism about the partnership, stating, “We look forward to collaborating with Avance Clinical, a global CRO, and this MOU marks an important starting point to further enhance our unique strengths. We anticipate maintaining a close relationship to play a leading role in the clinical trial field”.

Dong-A University Hospital, Clinical Trial Center (Pusan) is known for its comprehensive clinical trial infrastructure and experienced research teams. The collaboration with Dong-A aims to deepen research ties, particularly in early-phase clinical trials, offering expanded opportunities for clients seeking to develop breakthrough therapies across multiple therapeutic areas.

Signed on October 30, 2024

Sung Yong Oh, Director of the Dong-A University Hospital, Clinical Trial Center expressed confidence in the newly formed collaboration, stating, “This partnership with Avance Clinical marks a pivotal moment for us. By working together, we can further enhance our research infrastructure and significantly contribute to global healthcare innovations. We are confident that this collaboration will accelerate the development of advanced medical technologies and treatments”.

The MoU signings and Avance Clinical’s participation in KoNECT reflect the company’s ongoing commitment to expanding its global footprint. KoNECT 2024, co-hosted by the Korea National Enterprise for Clinical Trials (KoNECT) and the Ministry of Health and Welfare (MOHW), is a premier event for thought leaders and industry professionals to discuss innovations in clinical trials across the Asia-Pacific region.